medi, a leading manufacturer of medical devices, has introduced restiffic, a drug-free treatment for patients with restless legs syndrome (RLS), in the UK.
Between 5-6.5 million people in the UK suffer from the neurological disorder, with more women than men suffering with the condition. RLS usually occurs when at rest, mostly in the evening and during the night. Symptoms include creeping, cramping, crawling or tingling sensations, either in one or both legs. The irresistible twitching of the leg muscles forces patients to want to move their legs, in order to alleviate symptoms. Restiffic, with its patented technology, specifically targets this.
The foot wrap device promotes a gentle relaxing pressure on specific areas of the foot offering a comfortable, soothing effect. This significantly reduces the uncontrollable impulse to move the legs. In a clinical study restiffic reduced RLS symptoms by 69% compared to pre-therapy levels and allowed for a largely undisturbed night sleep with all patients either “much” or “very much” improved during therapy.
Thanks to its anatomic design, restiffic is easily adjustable to the patients’ needs and offers soothing relief. Easy application and removal makes nightly use simple and the lightweight and compact size, along with the protective cover-up, encourages a restful night’s sleep. The Flexor-T pad cradles the ball of the foot for an intuitive fit and topical pressure can be adjusted to customise therapy. Restiffic is a new option to treat RLS symptoms effectively and drug-free, avoiding unwanted adverse effects from prescribed medication.
About restless legs syndrome
Specialised neurologists believe a mild dopamine dysfunction of the brain leads to a wrong signal from the brain to the feet and back to the brain causing RLS symptoms. For some patients, these symptoms can be endured well, but for many they lead to chronic lack of sleep as well as physical exhaustion and depression. Whenever patients are looking for relaxation – whether reading, watching TV or going to the theatre, for example – they will experience immediate discomfort from their RLS symptoms. This inevitably results in a chronic impairment in many areas of their life.
Usually, treatment for RLS would consist of the administration of prescription drugs such as dopaminergic drugs or even opioids. However, these drugs can cause side effects such as dizziness, nausea and sometimes the risk of addiction. This makes restiffic a valuable therapeutic option for patients who do not wish to take or cannot tolerate standard drug therapy.
For more information about restiffic visit medi.biz/restiffic-uk and medi.biz/restiffic-uk-shop.